Factor IX (AlphaNine SD / AlphaNine)

Agonistic bispecific antibodies: an emerging frontier in antibody therapeutics.

Yang Jinyan J, Deng Junwen J, Sun Zhaowei Z, Liu Yumeng Y et al.

Antibody-based cancer therapies have long been valued for their high target specificity and favorable safety profiles compared with conventional chemotherapy and radiotherapy. The field has expanded rapidly, driven in part by advances in antibody engineering and the emergence of antibody-derived modalities. Among these, bispecific antibodies (bsAbs) and agonists have independently reshaped the therapeutic landscape by enabling novel mechanisms of action. However, the clinical development of agonists has been hampered by challenges such as systemic toxicity arising from excessive receptor activation and limited efficacy associated with inadequate receptor clustering or context-dependent signaling. To address these limitations, a distinct class of engineered molecules-agonistic bsAbs-has recently emerged as a promising therapeutic strategy. By spatially and contextually restricting receptor activation, these antibodies aim to enhance agonistic potency while improving safety and therapeutic index. Notably, in addition to their roles in cancer therapy, agonistic bsAbs also exhibit therapeutic potential in metabolic diseases. In this review, we classify agonistic bsAbs according to the nature of the receptors requiring activation, including immune co-stimulatory receptors, death receptors, and growth factor receptors. For each category, we summarize representative agonistic bsAbs, with a focus on their molecular design principles, mechanisms of action, preclinical and clinical progress, and current limitations. Together, this overview highlights agonistic bispecific antibodies as an evolving and versatile platform with the potential to redefine antibody-based therapeutics.

Building a precision therapeutics program at a tertiary care children's hospital.

Hamilton Luke L, Trinkman Heidi H, Carrasco Diana D, Smith Kaitlin K et al.

The development of the developmental dysplasia of the hip awareness scale and examination of its psychometric properties.

Yolcu Betül B, Tiryaki Öznur Ö

This study aimed to develop the "Developmental Dysplasia of the Hip Awareness Scale (DDHAS) and assess its psychometric properties. The methodological study included mothers (n = 400) with infants aged 0-2 months. Data were collected using a socio-demographic information form and the draft of the DDHAS. Factor analysis and reliability analyses were performed to evaluate the scale's psychometric properties. The data were analyzed using IBM SPSS Statistics 23 and IBM SPSS AMOS 23. Exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) of the scale revealed a structure consisting of 24 items and three sub-dimensions. The factor loadings of the scale were found to be above 0.40. Following CFA, the fit indices were at adequate levels. The Cronbach's alpha for the entire scale was 0.878, while the values for the sub-dimensions ranged from 0.850 to 0.913, indicating good internal consistency. Based on the findings obtained, the DDHAS demonstrated acceptable psychometric properties and may be used as a measurement instrument to assess the level of awareness of developmental dysplasia of the hip among mothers with infants aged 0-2 months. Midwives and nurses can use the Developmental Dysplasia of the Hip Awareness Scale in their clinical practice and training to assess mothers' awareness of developmental dysplasia of the hip. It is also recommended that the scale be adapted and validated for use in different cultural contexts.

How diet therapy affects obesity-associated depressive symptoms: from mechanism to therapeutics.

Wang Ruiqing R, Chen Zhilin Z, Wang Yiwei Y, Zhang Yangpu Y et al.

Obesity stands as a formidable 21st-century public health crisis, with its capacity to aggravate depressive symptoms gaining increasing clinical attention. Traditional treatment models often treat these two conditions separately. However, recent research evidence suggests a complex network linking obesity and depressive symptoms across metabolism, behavior, and mental health, with dietary patterns proposed as a key upstream modulator of both metabolic and psychological pathways. The specific mechanisms by which diet influences obesity and depressive symptoms remain unclear. Therefore, this narrative review focuses on analyzing molecular connections between diet, obesity, and depressive symptoms, including adipose tissue inflammation, the gut-brain axis, the hypothalamus-pituitary-adrenal axis, insulin and brain-derived neurotrophic factor levels, and neuroplasticity. We discuss the possible pathways and effects of different diet therapies in regulating metabolism and simultaneously impacting mental health, including calorie restriction diet, intermittent fasting, ketogenic diet, low glycemic index diet, plant-based diet, Mediterranean diet, Dietary Approaches to Stop Hypertension, among others. This review aims to provide a scientific basis for precision nutrition and personalized, sustainable diet therapies in clinical practice, promoting awareness and improving treatment strategies for depressive symptoms in obese patients.